Amy Scurlock
Concepts (267)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Food Hypersensitivity | 13 | 2024 | 96 | 4.130 |
Why?
| Desensitization, Immunologic | 25 | 2024 | 106 | 3.430 |
Why?
| Peanut Hypersensitivity | 20 | 2024 | 89 | 3.410 |
Why?
| Allergens | 24 | 2024 | 144 | 3.120 |
Why?
| Food Supply | 3 | 2023 | 99 | 1.230 |
Why?
| Hypersensitivity | 4 | 2023 | 82 | 1.140 |
Why?
| Chlamydia Infections | 8 | 2018 | 119 | 1.010 |
Why?
| Egg Hypersensitivity | 7 | 2021 | 26 | 1.000 |
Why?
| Antigens, Plant | 3 | 2020 | 15 | 0.900 |
Why?
| Administration, Oral | 21 | 2022 | 459 | 0.830 |
Why?
| Immunoglobulin E | 14 | 2021 | 93 | 0.800 |
Why?
| Anaphylaxis | 5 | 2021 | 71 | 0.770 |
Why?
| Allergy and Immunology | 2 | 2018 | 15 | 0.760 |
Why?
| Child | 35 | 2024 | 7341 | 0.750 |
Why?
| Immunotherapy | 2 | 2020 | 263 | 0.740 |
Why?
| Rhinitis, Allergic, Seasonal | 1 | 2018 | 5 | 0.670 |
Why?
| Immune Tolerance | 6 | 2022 | 104 | 0.650 |
Why?
| Age Factors | 1 | 2020 | 1198 | 0.590 |
Why?
| Child, Preschool | 26 | 2024 | 4147 | 0.590 |
Why?
| Chlamydia muridarum | 5 | 2018 | 53 | 0.530 |
Why?
| Interleukin-17 | 2 | 2013 | 38 | 0.500 |
Why?
| Humans | 53 | 2024 | 54284 | 0.470 |
Why?
| Uterine Cervicitis | 2 | 2013 | 4 | 0.440 |
Why?
| Adolescent | 22 | 2024 | 6897 | 0.430 |
Why?
| Th1 Cells | 2 | 2010 | 50 | 0.400 |
Why?
| Gastrointestinal Tract | 2 | 2011 | 135 | 0.400 |
Why?
| Neutrophil Infiltration | 1 | 2010 | 29 | 0.390 |
Why?
| Guideline Adherence | 2 | 2013 | 148 | 0.390 |
Why?
| Th17 Cells | 1 | 2010 | 26 | 0.380 |
Why?
| Immunoglobulin G | 5 | 2020 | 226 | 0.350 |
Why?
| Eosinophilic Esophagitis | 2 | 2021 | 32 | 0.350 |
Why?
| Mouth | 1 | 2009 | 35 | 0.340 |
Why?
| Adult | 10 | 2024 | 14207 | 0.320 |
Why?
| Skin Tests | 6 | 2022 | 58 | 0.320 |
Why?
| Female | 32 | 2022 | 28441 | 0.310 |
Why?
| Macrophages | 1 | 2010 | 405 | 0.310 |
Why?
| Primary Health Care | 1 | 2011 | 401 | 0.310 |
Why?
| Emergency Service, Hospital | 1 | 2011 | 539 | 0.290 |
Why?
| Prognosis | 6 | 2021 | 2118 | 0.290 |
Why?
| Reproductive Tract Infections | 2 | 2018 | 17 | 0.280 |
Why?
| Antibodies, Monoclonal | 1 | 2010 | 562 | 0.270 |
Why?
| Anti-Allergic Agents | 2 | 2024 | 16 | 0.270 |
Why?
| Fear | 1 | 2006 | 87 | 0.260 |
Why?
| Food | 2 | 2018 | 67 | 0.260 |
Why?
| Life Style | 1 | 2006 | 156 | 0.260 |
Why?
| Young Adult | 8 | 2024 | 4318 | 0.260 |
Why?
| Follow-Up Studies | 5 | 2021 | 2387 | 0.240 |
Why?
| Infant | 14 | 2024 | 3817 | 0.240 |
Why?
| Male | 24 | 2022 | 27334 | 0.230 |
Why?
| 2S Albumins, Plant | 2 | 2020 | 8 | 0.230 |
Why?
| Flow Cytometry | 3 | 2018 | 546 | 0.230 |
Why?
| Double-Blind Method | 7 | 2022 | 742 | 0.230 |
Why?
| Candy | 1 | 2002 | 3 | 0.230 |
Why?
| Pelvic Inflammatory Disease | 2 | 2013 | 11 | 0.220 |
Why?
| Nutritional Status | 1 | 2023 | 158 | 0.220 |
Why?
| Basophils | 4 | 2015 | 16 | 0.220 |
Why?
| Plasmids | 3 | 2018 | 180 | 0.210 |
Why?
| Toll-Like Receptor 8 | 1 | 2021 | 3 | 0.200 |
Why?
| Enteritis | 1 | 2021 | 20 | 0.200 |
Why?
| Mosaicism | 1 | 2021 | 18 | 0.200 |
Why?
| Immunologic Deficiency Syndromes | 1 | 2021 | 20 | 0.200 |
Why?
| B-Lymphocytes | 2 | 2021 | 176 | 0.200 |
Why?
| Gastritis | 1 | 2021 | 35 | 0.200 |
Why?
| T-Lymphocytes | 3 | 2021 | 373 | 0.200 |
Why?
| Pancytopenia | 1 | 2021 | 40 | 0.190 |
Why?
| Injections, Subcutaneous | 1 | 2020 | 58 | 0.190 |
Why?
| Health Promotion | 1 | 2023 | 300 | 0.190 |
Why?
| Immunity, Mucosal | 2 | 2010 | 19 | 0.190 |
Why?
| Chlamydia trachomatis | 2 | 2011 | 42 | 0.180 |
Why?
| Treatment Outcome | 10 | 2022 | 5604 | 0.170 |
Why?
| Pollen | 1 | 2018 | 2 | 0.170 |
Why?
| Interferon-gamma | 2 | 2018 | 195 | 0.170 |
Why?
| Wiskott-Aldrich Syndrome Protein | 1 | 2018 | 2 | 0.160 |
Why?
| Wiskott-Aldrich Syndrome | 1 | 2018 | 3 | 0.160 |
Why?
| Quality of Life | 2 | 2022 | 922 | 0.160 |
Why?
| Animals | 8 | 2018 | 14385 | 0.160 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2019 | 180 | 0.160 |
Why?
| United States | 4 | 2022 | 5217 | 0.150 |
Why?
| Academic Medical Centers | 1 | 2018 | 141 | 0.150 |
Why?
| Eosinophils | 1 | 2017 | 36 | 0.150 |
Why?
| Anti-Bacterial Agents | 3 | 2013 | 820 | 0.150 |
Why?
| Faculty, Medical | 1 | 2018 | 100 | 0.150 |
Why?
| Esophagus | 1 | 2017 | 79 | 0.150 |
Why?
| Immunologic Factors | 3 | 2022 | 130 | 0.140 |
Why?
| Health Literacy | 1 | 2019 | 141 | 0.140 |
Why?
| Inflammation | 1 | 2021 | 674 | 0.140 |
Why?
| Basophil Degranulation Test | 1 | 2015 | 3 | 0.130 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 673 | 0.130 |
Why?
| Oviducts | 2 | 2013 | 7 | 0.130 |
Why?
| Diagnostic Errors | 2 | 2013 | 74 | 0.130 |
Why?
| Cytokines | 3 | 2021 | 676 | 0.120 |
Why?
| Interleukin-23 | 1 | 2013 | 10 | 0.120 |
Why?
| Meningitis, Pneumococcal | 1 | 2013 | 6 | 0.120 |
Why?
| Interleukin-1 Receptor-Associated Kinases | 1 | 2013 | 11 | 0.120 |
Why?
| Egg Proteins | 2 | 2019 | 19 | 0.120 |
Why?
| Interleukins | 1 | 2013 | 39 | 0.120 |
Why?
| Toll-Like Receptor 2 | 2 | 2011 | 29 | 0.120 |
Why?
| Mycobacterium fortuitum | 1 | 2013 | 6 | 0.120 |
Why?
| Macrolides | 1 | 2013 | 17 | 0.110 |
Why?
| Manikins | 1 | 2013 | 40 | 0.110 |
Why?
| Immunoglobulins, Intravenous | 1 | 2013 | 55 | 0.110 |
Why?
| Patient Selection | 1 | 2015 | 286 | 0.110 |
Why?
| Emergency Medicine | 1 | 2013 | 60 | 0.110 |
Why?
| Clarithromycin | 1 | 2013 | 40 | 0.110 |
Why?
| Mice, Inbred C57BL | 3 | 2018 | 1999 | 0.110 |
Why?
| Mass Screening | 2 | 2018 | 370 | 0.110 |
Why?
| Methicillin | 1 | 2012 | 9 | 0.110 |
Why?
| Clindamycin | 1 | 2012 | 15 | 0.110 |
Why?
| Arkansas | 5 | 2019 | 2100 | 0.110 |
Why?
| T-Lymphocytes, Regulatory | 2 | 2009 | 85 | 0.110 |
Why?
| Mice, Knockout | 2 | 2013 | 926 | 0.100 |
Why?
| Gonorrhea | 1 | 2011 | 15 | 0.100 |
Why?
| Drug Resistance, Bacterial | 1 | 2012 | 81 | 0.100 |
Why?
| Medication Errors | 1 | 2011 | 26 | 0.100 |
Why?
| Influenza Vaccines | 1 | 2011 | 42 | 0.100 |
Why?
| Epinephrine | 3 | 2019 | 97 | 0.100 |
Why?
| Medicine, Chinese Traditional | 1 | 2010 | 8 | 0.100 |
Why?
| Adaptive Immunity | 1 | 2011 | 39 | 0.100 |
Why?
| T-Lymphocyte Subsets | 1 | 2010 | 41 | 0.100 |
Why?
| Eye Infections, Bacterial | 1 | 2011 | 35 | 0.100 |
Why?
| Mice | 5 | 2018 | 6413 | 0.100 |
Why?
| Membrane Proteins | 2 | 2013 | 389 | 0.100 |
Why?
| Anemia, Hemolytic | 1 | 2010 | 12 | 0.100 |
Why?
| Cervix Uteri | 1 | 2010 | 53 | 0.090 |
Why?
| Influenza, Human | 1 | 2011 | 120 | 0.090 |
Why?
| Clinical Protocols | 1 | 2010 | 122 | 0.090 |
Why?
| Dermatitis, Atopic | 1 | 2012 | 92 | 0.090 |
Why?
| Neutrophils | 1 | 2011 | 154 | 0.090 |
Why?
| Pediatrics | 1 | 2013 | 323 | 0.090 |
Why?
| Antigenic Variation | 1 | 2009 | 5 | 0.090 |
Why?
| Retrospective Studies | 5 | 2013 | 6432 | 0.090 |
Why?
| Antibodies, Bacterial | 1 | 2009 | 38 | 0.090 |
Why?
| Staphylococcal Infections | 1 | 2012 | 300 | 0.080 |
Why?
| Gene Expression Regulation, Bacterial | 1 | 2011 | 244 | 0.080 |
Why?
| Risk Factors | 4 | 2019 | 3935 | 0.080 |
Why?
| Immunization | 2 | 2019 | 95 | 0.080 |
Why?
| Staphylococcus aureus | 1 | 2012 | 361 | 0.080 |
Why?
| Cystic Fibrosis | 1 | 2010 | 157 | 0.080 |
Why?
| Clinical Trials as Topic | 1 | 2010 | 490 | 0.080 |
Why?
| Fallopian Tubes | 1 | 2007 | 25 | 0.080 |
Why?
| Genital Diseases, Female | 1 | 2007 | 22 | 0.080 |
Why?
| Treatment Failure | 2 | 2020 | 139 | 0.070 |
Why?
| Diagnosis, Differential | 2 | 2013 | 1136 | 0.070 |
Why?
| Risk Assessment | 1 | 2010 | 1361 | 0.070 |
Why?
| Bacterial Proteins | 1 | 2009 | 454 | 0.060 |
Why?
| Receptors, Interferon | 1 | 2004 | 5 | 0.060 |
Why?
| Homozygote | 1 | 2004 | 60 | 0.060 |
Why?
| Food Handling | 1 | 2004 | 37 | 0.060 |
Why?
| Sequence Deletion | 1 | 2004 | 99 | 0.060 |
Why?
| Gastrointestinal Diseases | 1 | 2005 | 126 | 0.060 |
Why?
| Administration, Sublingual | 2 | 2013 | 17 | 0.060 |
Why?
| Food Additives | 1 | 2002 | 9 | 0.060 |
Why?
| Apoptosis | 1 | 2009 | 1300 | 0.060 |
Why?
| Gelatin | 1 | 2002 | 26 | 0.060 |
Why?
| Pedigree | 1 | 2021 | 146 | 0.050 |
Why?
| Infusions, Subcutaneous | 1 | 2020 | 1 | 0.050 |
Why?
| Transdermal Patch | 1 | 2020 | 3 | 0.050 |
Why?
| Comorbidity | 2 | 2015 | 663 | 0.050 |
Why?
| Cooking | 1 | 2020 | 19 | 0.050 |
Why?
| Lymphocyte Activation | 1 | 2021 | 197 | 0.050 |
Why?
| Cell Line | 3 | 2011 | 1153 | 0.050 |
Why?
| Cells, Cultured | 2 | 2015 | 1737 | 0.050 |
Why?
| Ovum | 1 | 2019 | 7 | 0.050 |
Why?
| Diet Therapy | 1 | 2019 | 8 | 0.050 |
Why?
| Powders | 1 | 2019 | 32 | 0.050 |
Why?
| Immunity | 1 | 2019 | 36 | 0.040 |
Why?
| Infant, Newborn | 2 | 2018 | 2907 | 0.040 |
Why?
| Tertiary Healthcare | 1 | 2019 | 19 | 0.040 |
Why?
| Prospective Studies | 2 | 2017 | 2604 | 0.040 |
Why?
| Gene Regulatory Networks | 1 | 2019 | 124 | 0.040 |
Why?
| Staff Development | 1 | 2018 | 26 | 0.040 |
Why?
| Efficiency | 1 | 2018 | 36 | 0.040 |
Why?
| Social Responsibility | 1 | 2018 | 31 | 0.040 |
Why?
| Cell Differentiation | 1 | 2021 | 720 | 0.040 |
Why?
| Job Satisfaction | 1 | 2018 | 40 | 0.040 |
Why?
| Homeodomain Proteins | 1 | 2018 | 82 | 0.040 |
Why?
| Burnout, Professional | 1 | 2018 | 57 | 0.040 |
Why?
| Particulate Matter | 1 | 2017 | 56 | 0.040 |
Why?
| Transcriptome | 1 | 2019 | 346 | 0.040 |
Why?
| Leadership | 1 | 2018 | 114 | 0.040 |
Why?
| Self Efficacy | 1 | 2018 | 137 | 0.040 |
Why?
| Immunoblotting | 2 | 2009 | 134 | 0.040 |
Why?
| Predictive Value of Tests | 1 | 2020 | 1048 | 0.040 |
Why?
| Seasons | 1 | 2017 | 98 | 0.040 |
Why?
| Histamine Antagonists | 1 | 2016 | 22 | 0.040 |
Why?
| Proton Pump Inhibitors | 1 | 2017 | 84 | 0.040 |
Why?
| Disease Progression | 1 | 2019 | 913 | 0.040 |
Why?
| Program Evaluation | 1 | 2018 | 374 | 0.040 |
Why?
| Cell Line, Transformed | 2 | 2007 | 88 | 0.040 |
Why?
| Epigenesis, Genetic | 1 | 2019 | 399 | 0.040 |
Why?
| Communication | 1 | 2018 | 273 | 0.030 |
Why?
| Sensitivity and Specificity | 1 | 2018 | 923 | 0.030 |
Why?
| Prevalence | 1 | 2019 | 1025 | 0.030 |
Why?
| Environmental Exposure | 1 | 2017 | 205 | 0.030 |
Why?
| DNA Methylation | 1 | 2019 | 574 | 0.030 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2015 | 21 | 0.030 |
Why?
| Cohort Studies | 1 | 2019 | 1543 | 0.030 |
Why?
| Longitudinal Studies | 1 | 2017 | 746 | 0.030 |
Why?
| Middle Aged | 2 | 2024 | 13088 | 0.030 |
Why?
| Emergency Treatment | 1 | 2013 | 32 | 0.030 |
Why?
| Ofloxacin | 1 | 2013 | 10 | 0.030 |
Why?
| Plant Proteins | 1 | 2013 | 72 | 0.030 |
Why?
| Ceftriaxone | 1 | 2013 | 29 | 0.030 |
Why?
| Cross-Sectional Studies | 1 | 2019 | 1693 | 0.030 |
Why?
| Metronidazole | 1 | 2013 | 30 | 0.030 |
Why?
| Amikacin | 1 | 2013 | 19 | 0.030 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2016 | 596 | 0.030 |
Why?
| Outpatient Clinics, Hospital | 1 | 2013 | 44 | 0.030 |
Why?
| Symptom Assessment | 1 | 2013 | 38 | 0.030 |
Why?
| Glycoproteins | 1 | 2013 | 132 | 0.030 |
Why?
| Antibiotic Prophylaxis | 1 | 2013 | 67 | 0.030 |
Why?
| Doxycycline | 1 | 2013 | 46 | 0.030 |
Why?
| Azithromycin | 1 | 2013 | 42 | 0.030 |
Why?
| International Classification of Diseases | 1 | 2013 | 65 | 0.030 |
Why?
| Antibody Affinity | 1 | 2012 | 11 | 0.030 |
Why?
| Sexually Transmitted Diseases | 1 | 2013 | 49 | 0.030 |
Why?
| Urticaria | 1 | 2013 | 24 | 0.030 |
Why?
| Eggs | 1 | 2012 | 10 | 0.030 |
Why?
| Epitopes | 1 | 2012 | 89 | 0.030 |
Why?
| Equipment Design | 1 | 2013 | 318 | 0.030 |
Why?
| Age of Onset | 1 | 2012 | 117 | 0.030 |
Why?
| Hospitals, University | 1 | 2012 | 89 | 0.030 |
Why?
| Patient Care Team | 1 | 2013 | 273 | 0.030 |
Why?
| Trachoma | 1 | 2011 | 5 | 0.030 |
Why?
| Recurrence | 1 | 2013 | 690 | 0.020 |
Why?
| Glycogen Synthase | 1 | 2011 | 1 | 0.020 |
Why?
| Guinea Pigs | 1 | 2011 | 89 | 0.020 |
Why?
| Chromosomes, Bacterial | 1 | 2011 | 17 | 0.020 |
Why?
| Microbial Sensitivity Tests | 1 | 2012 | 290 | 0.020 |
Why?
| Inclusion Bodies | 1 | 2011 | 23 | 0.020 |
Why?
| Glycogen | 1 | 2011 | 45 | 0.020 |
Why?
| Cell Separation | 1 | 2011 | 107 | 0.020 |
Why?
| Genetic Loci | 1 | 2011 | 58 | 0.020 |
Why?
| Hospitals, Pediatric | 1 | 2012 | 272 | 0.020 |
Why?
| Drug Hypersensitivity | 1 | 2010 | 41 | 0.020 |
Why?
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 314 | 0.020 |
Why?
| Rabbits | 1 | 2011 | 425 | 0.020 |
Why?
| Virulence | 1 | 2011 | 194 | 0.020 |
Why?
| Pain | 1 | 2013 | 405 | 0.020 |
Why?
| Clinical Competence | 1 | 2013 | 446 | 0.020 |
Why?
| Practice Guidelines as Topic | 1 | 2013 | 492 | 0.020 |
Why?
| Antibody Specificity | 1 | 2009 | 48 | 0.020 |
Why?
| Diphenhydramine | 1 | 2009 | 20 | 0.020 |
Why?
| Microarray Analysis | 1 | 2009 | 84 | 0.020 |
Why?
| Intestinal Mucosa | 1 | 2011 | 259 | 0.020 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2011 | 474 | 0.020 |
Why?
| Time Factors | 1 | 2016 | 3213 | 0.020 |
Why?
| Albuterol | 1 | 2009 | 58 | 0.020 |
Why?
| Glucose | 1 | 2011 | 366 | 0.020 |
Why?
| Bronchodilator Agents | 1 | 2009 | 74 | 0.020 |
Why?
| Gene Expression | 1 | 2011 | 664 | 0.020 |
Why?
| Immunization, Secondary | 1 | 2007 | 17 | 0.020 |
Why?
| Down-Regulation | 1 | 2009 | 388 | 0.020 |
Why?
| Mice, Inbred C3H | 1 | 2007 | 82 | 0.020 |
Why?
| Epitopes, T-Lymphocyte | 1 | 2007 | 33 | 0.020 |
Why?
| Immunity, Innate | 1 | 2007 | 114 | 0.020 |
Why?
| Algorithms | 1 | 2010 | 697 | 0.020 |
Why?
| Disease Models, Animal | 1 | 2011 | 1639 | 0.020 |
Why?
| Mycobacterium avium Complex | 1 | 2004 | 5 | 0.020 |
Why?
| Genes, Dominant | 1 | 2004 | 21 | 0.020 |
Why?
| Genes, Recessive | 1 | 2004 | 18 | 0.020 |
Why?
| Mycobacterium avium-intracellulare Infection | 1 | 2004 | 10 | 0.020 |
Why?
| Phenotype | 1 | 2007 | 820 | 0.020 |
Why?
| Recombinant Fusion Proteins | 1 | 2004 | 206 | 0.010 |
Why?
| Transfection | 1 | 2004 | 399 | 0.010 |
Why?
| Osteomyelitis | 1 | 2004 | 122 | 0.010 |
Why?
| Signal Transduction | 1 | 2007 | 1753 | 0.010 |
Why?
|
|
Scurlock's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|